MetaCap

Oculis (OCS) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed Oculis (OCS) over the past year, gaining 57.1% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -32.5% for OVID. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $393.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OCS-63.34%OVID+57.14%
+120%+23%-73%
Nov 21, 20251 yearNov 20, 2026
OCS-27.66%OVID-36.05%
+251%+71%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OCS versus OVID key metrics
MetricOCSOVID
Share price$7.06$2.20
Market cap$393.35M$415.21M
1-day change-5.11%-5.98%
YTD return-64.65%+34.97%
1-year return-63.34%+57.14%
5-year return-27.29%-32.52%
EPS (TTM)$-1.69$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$7.25M
Revenue growth (YoY)—+1181.27%
Net income (latest FY)—$-17.41M
Operating margin—-585.20%
Net margin—-240.13%
52-week high$34.48$3.11
52-week low$6.78$1.26
Distance from 52-week high-79.52%-29.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+407.79%+179.55%
Average volume272.83K1.98M
Shares outstanding55.72M188.73M
Employees6023
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OVID has outperformed OCS by 120.5 percentage points over the past year.

About Oculis

OCS stock →

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

OCS vs OVID FAQ

Which is bigger, Oculis or Ovid Therapeutics?

Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $393.35M for Oculis (OCS).

Which stock has performed better over the past year, OCS or OVID?

OVID returned +57.14% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.

Are Oculis and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons